Delayed neurotoxicity of intraventricular interleukin-2: a case report.
A case is reported of a 40 year old woman treated with intraventricular IL-2 for leptomeningeal disease who developed progressive cognitive dysfunction. This deterioration started 3 months post-treatment and worsened over the ensuing 4 years. MRI revealed white matter abnormalities that were not present on the pretreatment scan. Although free of disease, the patient has a subcortical dementia and is unable to work. The potential for progressive brain injury and subsequent disability related to intraventricular IL-2 therapy is discussed.
Meyers
C A
CA
Department of Neuro-Oncology, University of Texas, Anderson Cancer Center, Houston.
Yung
W K
WK
D000328:Adult; D001927:Brain Diseases / Q000139:chemically induced*; D002493:Central Nervous System Diseases / Q000188:drug therapy*; D003072:Cognition Disorders / Q000139:chemically induced; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007276:Injections, Intraventricular; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects*; D013997:Time Factors
D007376:Interleukin-2